Braxia Scientific Corp.

Equities

BRAX

CA1057361026

Healthcare Facilities & Services

Delayed Canadian Securities Exchange Other stock markets 09:30:00 2024-04-29 am EDT			5-day change	1st Jan Change
0.01 ^CAD	0.00%		+100.00%	0.00%

Feb. 29	Braxia Scientific Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Braxia Scientific Corp. Announces Board Changes	CI

Braxia Scientific Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023

November 28, 2023

Braxia Scientific Corp. reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was CAD 0.594082 million compared to CAD 0.455263 million a year ago. Net loss was CAD 0.272832 million compared to CAD 2.34 million a year ago.
For the six months, sales was CAD 1.19 million compared to CAD 0.872763 million a year ago. Net loss was CAD 1.08 million compared to CAD 3.31 million a year ago.

Latest news about Braxia Scientific Corp.

Braxia Scientific Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 29	CI
Braxia Scientific Corp. Announces Board Changes	Nov. 30	CI
Braxia Scientific Corp. Announces CFO Changes	Nov. 30	CI
Braxia Scientific Corp. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 28	CI
Braxia Scientific Corp. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-28	CI
Braxia Scientific Corp. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-30	CI
Braxia Scientific Provides Operations Update	23-06-09	MT
Irwin Naturals Launches New Product in Canada	23-03-24	MT
Irwin Naturals Brief: Says Cannabis Products Launch Nationwide in Canada	23-03-24	MT
Irwin Naturals Closes Purchase of Ketamine Media	23-03-22	MT
Irwin Naturals Brief: CEO of Irwin Naturals, Klee Irwin, Expressed Disappointment on the Announcement, But Recognized the Decision was "Based on a Lack of a Clear Business Rationale for the Company to move forward with the Transaction"	23-03-16	MT
Irwin Naturals Brief: Says has terminated Non-binding amended and restated letter of intent for a business combination with Braxia Scientific Corp.	23-03-16	MT
Irwin Naturals Inc. cancelled the acquisition of Braxia Scientific Corp..	23-03-15	CI
Braxia Scientific Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-28	CI
Braxia Scientific Corp. announced that it has received CAD 0.513 million in funding	23-02-26	CI
Irwin Naturals Closes Purchase of Kentucky Clinic	23-02-21	MT
Braxia Scientific Corp. announced that it expects to receive CAD 1.5 million in funding	23-02-06	CI
Refile: Irwin Naturals Secures Credit Facility For Up To US$60 Million	23-02-02	MT
Irwin Naturals Brief: Says Secured US$40 Million of Financing for its Current Operations including Psychedelic Mental Health Clinic Rollup, Potential for up to $60 Million	23-02-02	MT
Irwin Naturals Brief: Says Signed Letter of Intent to Acquire Braxia Scientific	23-01-30	MT
Irwin Naturals Reports Letter of Intent to Purchase Braxia Scientific	23-01-27	MT
Irwin Naturals Brief: And a deemed value per subordinate voting share and/or proportionate voting share of Irwin equal to the greater of US$3.00 and the volume weighted average trading price of Irwin Shares on the CSE	23-01-27	MT
Irwin Naturals Brief: Under the terms of the LOI, Irwin Prepared to Offer a purchase price per Braxia Share based upon a valuation of the outstanding Braxia Shares of US$30 Million	23-01-27	MT
Irwin Naturals Brief: Signing Letter of Intent to Acquire Braxia Scientific	23-01-27	MT
Irwin Naturals Inc. signed letter of intent to acquire Braxia Scientific Corp. for CAD 39.9 million.	23-01-26	CI

Chart Braxia Scientific Corp.

Duration

Period

More charts

Company Profile

Braxia Scientific Corp. is a Canada-based company, which is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing drugs and delivery methods. The Company seeks to develop ketamine and derivatives and other psychedelic products from its Internet protocol (IP) development platform. The Company has clinic operations in the Canadian cities of Mississauga, Toronto, Kitchener-Waterloo, Ottawa and Montreal. The Company, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., it operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, Kitchener and Montreal. Its subsidiaries include Altmed Capital Corp., Artisan Growers Ltd., KetaMD, Inc., Novo Formulations Ltd. and Tassili Life Sciences Corp.

Sector

Healthcare Facilities & Services

Calendar

2024-07-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
BRAXIA SCIENTIFIC CORP.	0.00%	2.07M
CVS HEALTH CORPORATION	-14.18%	84.68B
HCA HEALTHCARE, INC.	+14.18%	81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+11.62%	29.59B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-11.84%	16.73B
FRESENIUS SE & CO. KGAA	-1.46%	16.36B
PURE HEALTH HOLDING	-31.58%	11.77B
FRESENIUS MEDICAL CARE AG	+1.42%	11.72B
DAVITA INC.	+28.92%	11.71B
EUROFINS SCIENTIFIC SE	-0.92%	11.66B

Other Healthcare Facilities & Services